Last week, Rule Breakers pick Millennium Pharmaceuticals (NASDAQ:MLNM) released upbeat and better-than-expected third-quarter financial results.

Millennium's stock price rightfully adjusts to whatever the future looks like for its lead drug, VELCADE. After the third quarter, its future undeniably looks brighter. Sales of the multiple myeloma treatment, which is marketed by Millennium and partner Johnson & Johnson (NYSE:JNJ), were up a much-higher-than-expected 32% vs. last year.

Based on the greater-than-expected sales growth with VELCADE, which came mostly from increased prescription demand rather than unsustainable price hikes, Millennium upped its top- and bottom-line forecasts for the year and now expects its GAAP net loss to be only in the $30 million to $35 million range. This is nearly half the amount it was expecting its 2007 loss to be as recently as July.

Following a strongly positive phase 3 study in the front-line multiple myeloma setting, Millennium also expects to file a marketing application to expand the VELCADE label to this earlier stage treatment setting by the end of the year. This improved outlook for VELCADE is what is causing the perceived weakened outlook for rival Celgene's (NASDAQ:CELG) multiple myeloma compounds this quarter.

As evidenced by the surge in shares of Biogen IDEC (NASDAQ:BIIB) and ImClone Systems (NASDAQ:IMCL) following rumors about big pharma interest in them and the buyout of MedImmune by AstraZeneca (NYSE:AZN) earlier in the year, any drugmaker in the biopharma sector with a respectable pipeline is coming under acquisition watch by pipeline-starved large-cap pharmas.

The potential for a buyout is NEVER an appropriate reason to invest in a drugmaker, but with 10 new molecular entities in its pipeline and a better outlook for its lead drug, I wonder how long it will be until rumors about a buyout of Millennium start popping up.

Looking for more Foolish drug stock coverage? Check out the Fool's Rule Breakers newsletter.

Biogen IDEC is an active pick of our  Stock Advisor newsletter, and Johnson & Johnson is a selection of the Income Investor newsletter.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool's disclosure policy is not subject to any buyout offers.